Scholarlink

<p>The use of paclitaxel-coated devices (PCDs) in peripheral arterial disease continues to generate interest and controversy. The PCD journey to date has been a story of highs and lows. The recently published SWEDEPAD 1 and 2 trials have rekindled discussion regarding efficacy and a potential link to mortality.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The ups and downs of paclitaxel-coated balloons and paclitaxel eluting stents: do the conclusions of SWEDEPAD 2 change our practice? Should we be concerned about mortality (again)?

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月27日

查看全文
  • Stefan Müller-Hülsbeck,
  • Fabrizio Fanelli,
  • Patrick Haage,
  • Mohamad Hamady,
  • Hicham Kobeiter,
  • Romaric Loffroy,
  • Gerard O’Sullivan,
  • Lakshmi A. Ratnam,
  • Catharina S. P. van Rijswijk,
  • Maria Antonella Ruffino,
  • Florian Wolf,
  • Robert A. Morgan

摘要

The use of paclitaxel-coated devices (PCDs) in peripheral arterial disease continues to generate interest and controversy. The PCD journey to date has been a story of highs and lows. The recently published SWEDEPAD 1 and 2 trials have rekindled discussion regarding efficacy and a potential link to mortality.